<DOC>
	<DOCNO>NCT02447003</DOCNO>
	<brief_summary>This two-part study pembrolizumab monotherapy participant metastatic triple-negative breast cancer ( mTNBC ) . Part 1 study examine efficacy safety pembrolizumab monotherapy first line treatment . Part 2 study , do , expand investigation pembrolizumab treatment subgroup participant Part 1 start enrollment Part 1 complete .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Monotherapy Metastatic Triple-Negative Breast Cancer ( MK-3475-086/KEYNOTE-086 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>For purpose study , neoadjuvant and/or adjuvant chemotherapy regimens count prior line therapy . For Cohorts A C : At least one systemic treatment metastatic breast cancer Documented disease progression recent therapy Prior treatment must include anthracycline taxane neoadjuvant , adjuvant , metastatic setting For Cohort B : No prior systemic treatment metastatic breast cancer PDL1positive mTNBC . For Cohort C : PDL1 strong positive mTNBC For cohort : mTNBC confirm central laboratory For biomarker analysis , adequate newly obtain core excisional biopsy metastatic tumor lesion previously irradiate Measurable metastatic disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Female participant childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication Male participant agree use adequate method contraception start first dose study therapy 120 day last dose study therapy Adequate organ function Currently participate receive study therapy , participate study investigational agent receive study therapy use investigational device within 4 week prior study Day 1 Prior anticancer monoclonal antibody ( mAb ) therapy direct antineoplastic treatment within 4 week prior study Day 1 Prior chemotherapy , target small molecule therapy , radiation therapy within least 2 week prior study Day 1 Not recover ( i.e. , â‰¤ Grade 1 baseline ) adverse event due agent administer within least 2 week prior study Day 1 Active autoimmune disease require systemic treatment past 2 year Diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study medication Known additional malignancy progress require active treatment within last 5 year . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin undergone potentially curative therapy , situ cervical cancer Radiographicallydetectable central nervous system ( CNS ) metastases and/or carcinomatous meningitis History pneumonitis require treatment steroid History interstitial lung disease Active infection require systemic therapy Known psychiatric substance abuse disorder would interfere cooperation requirement trial Pregnant , breastfeeding , expect conceive father child within project duration trial , start screen visit 120 day last dose trial medication Prior therapy antiPD1 , antiPDL1 , antiPDL2 agent agent direct another coinhibitory Tcell receptor ( e.g . CTLA4 , OX40 , CD137 ) participate Merck MK3475 trial Known history human immunodeficiency virus ( HIV ) Known active Hepatitis B C Received live vaccine within 30 day plan start study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>